Remove Development Remove Pharmacy Remove Regulation
article thumbnail

The drug industry continues to dare regulation

World of DTC Marketing

didn’t just offer to pay for the drug’s development cost so that the price could be set very low, but it’s about investors who penalized the company stock when they learned that COVID might be on the decline. The post The drug industry continues to dare regulation appeared first on World of DTC Marketing.com.

article thumbnail

Pharmacies Selling PSE: Remember to Train Employees and Self-Certify

FDA Law Blog

Attorney’s Office for the Western District of Texas announced that People’s Rx, a local chain operating five retail pharmacies and a compounding laboratory in the Austin area, agreed to pay $200,000 to settle allegations that it violated the Controlled Substances Act (“CSA”). Regulated sellers must limit daily sales of SCLPs to 3.6

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Available for Preorder: The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

Pharmacies and Pharmacy Benefit Managers. Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more.

article thumbnail

Professionals and Patients Offer Mixed Views on Retail Pharmacy Chains’ Enthusiasm About Trials

ACRP blog

As several retail pharmacy chains proclaim a rosy outlook for ongoing efforts to expand their services into the clinical trials arena in the wake of the pandemic, traditional study site personnel and patients interviewed on the topic offered more mixed and nuanced concerns about the prospects for near-term success for such ventures.

article thumbnail

Professionals and Patients Offer Mixed Views on Retail Pharmacy Chains’ Enthusiasm About Trials

ACRP blog

As several retail pharmacy chains proclaim a rosy outlook for ongoing efforts to expand their services into the clinical trials arena in the wake of the pandemic, traditional study site personnel and patients interviewed on the topic offered more mixed and nuanced concerns about the prospects for near-term success for such ventures.

article thumbnail

US FDA approves Pfizer’s migraine nasal spray Zavzpret

Pharmaceutical Technology

It is a third-generation, selective and structurally unique, small molecule CGRP receptor antagonist and is currently under clinical development with oral and intranasal formulations. The regulator granted the approval based on two pivotal placebo-controlled, double-blind, randomised trials.

article thumbnail

Navigating Local Considerations When Developing sIRB Reliance Policies

Advarra

When developing your institution’s consent language for sIRB use, consider what is truly necessary and limit your requirements to just those protecting participants or meeting other local requirements. conflict of interest, feasibility, pharmacy, etc.) are completed as required. The ceding institution (i.e.,